Document:

Exhibit 10.1

 

NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

FORM OF COMMON STOCK PURCHASE WARRANT

 

NIGHTFOOD
HOLDINGS INC.

 

	Warrant Shares: [_______]	Initial Exercise Date: [______], 2021

 

THIS COMMON STOCK PURCHASE WARRANT
(the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 15, 2026 (the
“Termination Date”) but not thereafter, to subscribe for and purchase from Nightfood Holdings, inc., a company incorporated
under the laws of the State of Nevada (the “Company”), up to [___] shares (as subject to adjustment hereunder, the
“Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal
to the Exercise Price, as defined in Section 2(b).

 

Section 1.Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Subscription Agreement (the
“Purchase Agreement”), dated April 16, 2021, among the Company and the purchasers signatory thereto.

 

     

     

    

 

Section 2.Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by email (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the
cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in
which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and
agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

b) Exercise
Price. The exercise price per share of Common Stock under this Warrant shall be $.30, subject to adjustment hereunder (the “Exercise
Price”).

 

c) Cashless
Exercise. If at any time after the six month anniversary of the Closing Date there is no effective registration statement registering,
or no current prospectus available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing ((A-B)(X)) by (A), where:

 

(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of
Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP
on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the
principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise
if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours
thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section
2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day
and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours”
on such Trading Day;

 

    2

     

    

 

(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and

 

(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.

 

If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding
period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.  The Company agrees
not to take any position contrary to this Section 2(c).

 

“Bid Price” means,
for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted
on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published
by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP” means, for
any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on
a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published
by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    3

     

    

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).

 

d) Mechanics
of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered
in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per
Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is
a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement
Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

    4

     

    

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.

 

    5

     

    

 

v. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.

 

vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

 

    6

     

    

 

e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.  Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon the written or oral request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall
be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    7

     

    

 

Section 3.Certain
Adjustments.

 

a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.

 

b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

c) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, merger, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however,
to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).

 

    8

     

    

 

d) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with
the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
“Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in
accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the
Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    9

     

    

 

e) Adjustment
Due to Dilutive Issuance. If, at any time when this Warrant is issued and outstanding, the Company issues or sells, or in accordance
with this subsection (e) (6) is deemed to have issued or sold, or otherwise disposes of or issues any shares of Common Stock for no consideration
or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection
therewith) less than the Exercise Price then in effect (a “Dilutive Issuance”), then immediately upon the Dilutive Issuance,
the Exercise Price will be reduced proportionately to the reduction in the Exercise Price then in effect, as calculated below, as a result
of that Dilutive Issuance. (By way of illustration, if the Exercise Price is then $0.30 and there is a Dilutive Issuance that would result
in the readjustment of the Exercise Price from $0.30 to $0.27 (a reduction of 10%) and the total number of Shares issuable upon exercise
of this Warrant will increase by 10%. Specifically, immediately upon a Dilutive Issuance the Exercise Price will be reduced to the price
determined by multiplying the Exercise Price in effect immediately prior to the Dilutive Issuance by a fraction, (A) the numerator of
which is an amount equal to the sum of (x) the number of shares of Common Stock actually outstanding immediately prior to the Dilutive
Issuance, plus (y) the quotient of the aggregate consideration, calculated as set forth in herein, received by the Company upon such Dilutive
Issuance divided by the Exercise Price in effect immediately prior to the Dilutive Issuance, and (B) the denominator of which is the Common
Stock Deemed Outstanding (as defined below) immediately after the Dilutive Issuance; provided that only one adjustment will be made for
each Dilutive Issuance. The term “Common Stock Deemed Outstanding” shall mean the number of shares of Common Stock actually
outstanding (not including shares of Common Stock held in the treasury of the Company), plus (A) pursuant to this Section 4(c) hereof,
the maximum total number of shares of Common Stock issuable upon the exercise of Options, as of the date of such issuance or grant of
such Options, if any, and (B) pursuant to Section 4)(c) hereof, the maximum total number of shares of Common Stock issuable upon conversion
or exchange of Convertible Securities, as of the date of issuance of such Convertible Securities, if any. For purposes of determining
the adjusted Exercise Price, the following will be applicable:

 

		a.	Issuance of Convertible Securities. If the Company in any manner issues or sells any Convertible
Securities, whether or not immediately convertible (other than where the same are issuable upon the exercise of these Warrants) and the
price per share for which Common Stock is issuable upon such conversion or exchange is less than the Exercise Price on the date of issuance,
then the maximum total number of shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities will,
as of the date of the issuance of such Convertible Securities, be deemed to be outstanding and to have been issued and sold by the Company
for such price per share. For the purposes of the preceding sentence, the “price per share for which Common Stock is issuable upon
such conversion or exchange” is determined by dividing (A) the total amount, if any, received or receivable by the Company as consideration
for the issuance or sale of all such Convertible Securities, plus the minimum aggregate amount of additional consideration, if any, payable
to the Company upon the conversion or exchange thereof at the time such Convertible Securities first become convertible or exchangeable,
by (B) the maximum total number of shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities.
No further adjustment to the Exercise Price will be made upon the actual issuance of such Common Stock upon conversion or exchange of
such Convertible Securities.

 

    10

     

    

 

		b.	Further Adjustment upon Change in Option Price or Exercise Price. If there is a change at any time
in (A) the amount of additional consideration payable to the Company upon the exercise of any Options; (B) the amount of additional consideration,
if any, payable to the Company upon the conversion or exchange of any Convertible Securities; or (C) the rate at which any Convertible
Securities are convertible into or exchangeable for Common Stock (other than under or by reason of provisions designed to protect against
dilution), the Exercise Price in effect at the time of such change will be readjusted to the Exercise Price which would have been in effect
at such time had such Options or Convertible Securities still outstanding provided for such changed additional consideration or changed
conversion rate, as the case may be, at the time initially granted, issued or sold.

 

		c.	Treatment of Expired Options and Unexercised Convertible Securities. If, in any case, the total
number of shares of Common Stock issuable upon exercise of any Option or upon conversion or exchange of any Convertible Securities is
not, in fact, issued and the rights to exercise such Option or to convert or exchange such Convertible Securities shall have expired or
terminated, the Exercise Price then in effect will be readjusted to the Exercise Price which would have been in effect at the time of
such expiration or termination had such Option or Convertible Securities, to the extent outstanding immediately prior to such expiration
or termination (other than in respect of the actual number of shares of Common Stock issued upon exercise or conversion thereof), never
been issued.

 

		d.	Calculation of Consideration Received. If any Common Stock, Options or Convertible Securities
are issued, granted or sold for cash, the consideration received therefor for purposes of the Holder’s Warrant will be the amount
received by the Company therefor, before deduction of reasonable commissions, underwriting discounts or allowances or other reasonable
expenses paid or incurred by the Company in connection with such issuance, grant or sale. In case any Common Stock, Options or Convertible
Securities are issued or sold for a consideration part or all of which shall be other than cash, the amount of the consideration other
than cash received by the Company will be the fair value of such consideration, except where such consideration consists of securities,
in which case the amount of consideration received by the Company will be the fair market value thereof as of the date of receipt. In
case any Common Stock, Options or Convertible Securities are issued in connection with any acquisition, merger or consolidation in which
the Company is the surviving corporation, the amount of consideration therefor will be deemed to be the fair value of such portion of
the net assets and business of the non-surviving corporation as is attributable to such Common Stock, Options or Convertible Securities,
as the case may be. The fair value of any consideration other than cash or securities will be determined in good faith by the Board of
Directors of the Company.

 

		e.	Exceptions to Dilutive issuances. Notwithstanding anything to the contrary herein, no adjustments
to this Warrant shall be made for: (i) any issuance of shares of Common Stock or other securities on conversion of Series B Preferred
Stock; or (ii) the issuance by the Company of up to 1,000,000 shares to consultants in any fiscal year.

 

    11

     

    

 

f) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g) Notice
to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    12

     

    

 

h) Voluntary
Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period
of time deemed appropriate by the board of directors of the Company.

 

Section 4.Transfer
of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b) New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

    13

     

    

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.

 

e) Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.

 

Section 5.Miscellaneous.

 

a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

    14

     

    

 

d) Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).

 

Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.

 

Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

 

e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.

 

    15

     

    

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

********************

 

(Signature Page Follows)

 

    16

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	NIGHTFOOD HOLDINGS INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    17

     

    

 

NOTICE OF EXERCISE

 

To:NIGHTFOOD
HOLDINGS INC.

 

(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment
shall take the form of (check applicable box):

 

[ ] in lawful money of the United States;
or

 

[ ] if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to the following
DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor. The undersigned is
an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: _______________________________________________________________________

Signature of Authorized Signatory of Investing Entity: _________________________________________________

Name of Authorized Signatory: ___________________________________________________________________

Title of Authorized Signatory: ____________________________________________________________________

Date: _______________________________________________________________________________________

 

     

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

 

(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 	 
	 	(Please Print)	 
	 	 	 
	Address:	 	 
	 	(Please Print)	 
	 	 	 
	Phone Number:	 	 
	 	 	 
	Email Address:	 	 
	 	 	 
	Dated: _______________ __, ______	 	 
	 	 	 
	Holder’s Signature: ____________________	 	 
	 	 	 
	Holder’s Address:  ____________________Exhibit
10.2

 

SUBSCRIPTION
AGREEMENT

 

THIS
SUBSCRIPTION AGREEMENT (the “Subscription Agreement” or “Agreement”) made as of this
_____ day of April, 2021 between NightFood Holdings, Inc., a corporation organized under the laws of the State of Nevada with
offices at 520 White Plains Road, Suite 500, Tarrytown, NY 10591 (the “Company”), and the undersigned (the
“Subscriber” and together with each of the other subscribers in the Offering (defined below), the “Subscribers”).

 

WHEREAS,
the Company desires to issue up to 5,000 shares of Series B Preferred Stock (the “B Preferred”) at $1,000 per share
for a total of up to $5,000,000 in a private placement (the “Offering”), provided, however, that up to $1,500,000
of the Offering may consist of non-cash consideration in the form of the conversion of $1,500,000 of the Debt (as defined in this Agreement)
into B Preferred. Each share of B Preferred is initially convertible, at the option of the Subscriber into five thousand shares of common
stock, par value $0.001 per share (the “Shares”) and five thousand five year redeemable common stock purchase warrants
(the “Warrants”, and together with the B Preferred, Shares into which the B Preferred is convertible into, and Shares
into which the Warrants are exercisable into, the “Securities”) with an exercise price of $0.30 (the full terms and conditions
of the B Preferred are set forth in the draft certificate of designation annexed hereto (the “Certificate of Designations”);
and

 

WHEREAS,
the Subscriber is delivering simultaneously herewith a completed confidential investor questionnaire (the “Questionnaire”),

 

NOW,
THEREFORE, for and in consideration of the promises and the mutual covenants hereinafter set forth, the parties hereto do hereby
agree as follows:

 

I.
SUBSCRIPTION FOR B PREFERRED AND REPRESENTATIONS BY AND COVENANTS OF SUBSCRIBER

 

1.1. Subscription
for Shares. Subject to the terms and conditions hereinafter set forth, the Subscriber hereby subscribes for and agrees to purchase
from the Company such number of shares of B Preferred as is set forth upon the signature page hereof; and the Company agrees to sell
such shares of B Preferred to the Subscriber for said purchase price subject to the Company’s right to sell to the Subscriber such
lesser number of shares of B Preferred as the Company may, in its sole discretion, deem necessary or desirable. The purchase price
is payable by a wire transfer or check made payable to “Frank J Hariton Attorney Trust Account” and delivered contemporaneously
with the execution and delivery of this Subscription Agreement to the Company’s address set forth above, Attn: Sean Folkson, CEO.
Mr. Hariton’s address is 1065 Dobbs Ferry Road, White Plains, New York 10607 and the wiring instructions for the account are
“Frank J Hariton, Attorney Trust Account, JP Morgan Chase Bank, NA, Account Number 746630250, ABA 021000021.

 

     

     

    

 

1.2. Reliance
on Exemptions. The Subscriber acknowledges that this Offering has not been reviewed by the United States Securities and Exchange
Commission (“SEC”) or any state agency because of the Company’s representations that this is intended
to be a nonpublic offering exempt from the registration requirements of the Shares Act of 1933, as amended (the “1933 Act”)
and state Shares laws. The Subscriber understands that the Company is relying in part upon the truth and accuracy of, and the Subscriber’s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Subscriber set forth herein in
order to determine the availability of such exemptions and the eligibility of the Subscriber to acquire the Shares.

 

1.3. Investment
Purpose. The Subscriber represents that the B Preferred are being purchased for his or her own account, for investment purposes only
and not for distribution or resale to others in contravention of the registration requirements of the 1933 Act. The Subscriber agrees
that it will not sell or otherwise transfer the B Preferred or the Shares or Warrants issuable upon conversion thereof unless they are
registered under the 1933 Act or unless an exemption from such registration is available.

 

1.4. Accredited
or Sophisticated Investor. The Subscriber represents and warrants that he, she or it is (i) an “accredited investor”
as such term is defined in Rule 501 of Regulation D promulgated under the 1933 Act, as indicated by its responses to the Questionnaire,
and that it is able to bear the economic risk of any investment in the B Preferred or (ii) either alone, or in conjunction with his advisor,
named below, has experience in financial matters to bear the understand the risks of this investment, that the investment being made
hereby represents less than 10% of his total assets, and that the Subscriber is able to bear the economic risk of this investment in
the B Preferred. The Subscriber further represents and warrants that the information furnished in the Questionnaire is accurate and complete
in all material respects.

 

1.5. RISK
OF INVESTMENT. THE SUBSCRIBER RECOGNIZES THAT THE PURCHASE OF THE B PREFERRED INVOLVES A HIGH DEGREE OF RISK INCLUDING, WITHOUT LIMITATION,
ANY AND ALL RISKS DISCUSSED IN THIS SUBSCRIPTION AGREEMENT. AN INVESTMENT IN THE COMPANY AND THE B PREFERRED MAY RESULT IN THE LOSS OF
A SUBSCRIBER’S ENTIRE INVESTMENT.

 

(a) Risk
of Loss of Investment. An investment in the Company and the B Preferred offered hereby involve a high degree of risk. An investment
in the B Preferred is suitable only for investors who can bear a loss of their entire investment. In order to evaluate these risks, the
Subscriber has carefully reviewed the materials filed under the Securities Exchange Act of 1934, as amended.

 

(b) Value
of B Preferred and the Shares and Warrants Issuable on Conversion of the B Preferred is Speculative. The terms of this offering have
been determined arbitrarily by the Company. There is no relationship between such terms and the Company’s assets, earnings, book
value and/or any other objective criteria of value.

 

    2

     

    

 

(c) Planned
Application of Proceeds. As of April 11, 2021, the Company had outstanding $2,446,200 principal amount of variable rate convertible
debt and approximately $216,000 in accrued interest due to one lender (collectively the “Debt”). Such lender and the
Company have entered into a letter agreement, dated April 12, 2021 (the “Letter Agreement”) which provides that conditioned
on the consummation of the Offering by April 16, 2021: (i) the Company will apply $1,300,000 of the proceeds of this offering to the
payment of the Debt (without any penalty, and with the Lender agreeing to forgive any default interest and approximately $300,000 in
prepayment penalties); (ii) that the Lender will convert $1,500,000 of the Debt into B Preferred with the same terms as the B Preferred
offered hereunder. The balance of the proceeds of the Offering will be applied by the Company as working capital principally to fund
operations. There is no commitment by any person to purchase B Preferred and there is no assurance that any number of B Preferred will
be sold. The Company’s may terminate this Offering prior to the expiration of the Offering Period. There is no assurance that the
Company will sell a sufficient number of B Preferred in this Offering on a timely basis or that the net proceeds after payment of debts
and other obligations will be adequate for the Company’s needs.

 

(d) Possible
Need for Additional Capital; Additional Private Placement. The net proceeds raised by the Company from this Offering will be used
immediately to prepay variable rate indebtedness and to fund the Company’s current operations. Depending on its success and the
advisability of expanding its production, the Company may require significant additional financing shortly after this Offering, regardless
of the net proceeds received.

 

(e) Restrictions
on Resale; Conversion and Exercise Procedures. The B Preferred and the Shares and Warrants that may be issued upon their conversion,
are “restricted” Shares and may not be resold or otherwise transferred except pursuant to an effective registration statement
or an exemption under the 1933 Act and applicable state or “blue sky” laws. Each of the form of Notice of Exercise (as defined
in the Warrants) included in the Warrants, and the form of Notice of Conversion (as defined in the Certificate of Designations) included
in the Certificate of Designations set forth the totality of the procedures required of the Buyers in order to exercise the Warrants
or convert the B Preferred.  Except as provided in the Warrants or Certificate of Designations with respect to the removal of any
restrictive legend, no additional legal opinion, other information or instructions shall be required of the Subscribers to exercise their
Warrants or convert their B Preferred.  The Company shall honor exercises of the Warrants and conversions of the B Preferred and
shall deliver the Shares, B Preferred, and Warrants in accordance with the terms, conditions and time periods set forth in the Certificate
of Designations and Warrants, respectively. For the avoidance of doubt, the parties hereto acknowledge and agree that no ink original
notices or medallion guarantees will be required by any Subscriber to convert any B Preferred or exercise any Warrants.

 

(f) Limited
Operating History; Development Stage Entity. The Company asks that the Subscriber review the Company’s filings under the Securities
Exchange Act of 1934, as amended, all of which can be viewed at www.sec.gov for an understanding of the risks involved in an investment
in the Company. The Company is a developmental stage entity. To evaluate the Company, investors should evaluate the Company in light
of the expenses, delays, uncertainties, and complications typically encountered by early-stage development businesses, many of which
are beyond the Company’s control. Early-stage development businesses commonly face risks such as the following:

 

		●	lack
                                            of sufficient capital;

 

		●	unanticipated
                                            problems, delays, and expenses relating to product development and implementation;

 

    3

     

    

 

		●	lack
                                            of intellectual property;

 

		●	licensing
                                            and marketing difficulties;

 

		●	competition;

 

		●	technological
                                            changes; and

 

		●	uncertain
                                            market acceptance of products and services.

 

(g) Dependence
upon the Company’s Founder. The Company is wholly dependent upon Sean Folkson,
its founder and CEO and sole director, for the operations and success of the Company. The loss of his services would have a material
adverse effect on the Company’s business, financial condition and results of operations.

 

(h) Capital
Structure of the Company. The following sets forth the capital structure of the Company prior to the sale of any Shares in this Offering.

 

(i) The
Company has Two Hundred Million (200,000,000) authorized shares of common stock and One Million (1,000,000) shares of blank check preferred
and no other class of Shares authorized.

 

(ii) The
Company has approximately 78,000,000 shares of Common Stock issued and outstanding and its principal shareholder, Sean Folkson, also
owns 1,000 shares of a class of super voting preferred stock that gives him voting control of the Company’s affairs

 

(iii) The
Company has no other Shares currently issued and outstanding, but there are options that are convertible into or exercisable for any
Shares of the Company.

 

The
following is a summary of the Company’s outstanding common stock purchase warrants. 

 

	 
Warrants:
	 	 	 	 	#
    of warrants	 	 	Strike
    Price	 	 	Exp
    Date
	AS Austin	 	 Non-affiliate	 	 	 	300,000	 	 	$	0.75	 	 	10/7/2021
	Michael
    Grandner	 	 Non-affiliate	 	 	 	500,000	 	 	$	0.15	 	 	 Valid
    until 90 days after he stops providing Advisory Services
	ReadySet
    Studios	 	 Non-affiliate	 	 	 	25,000	 	 	$	0.20	 	 	3/15/2021
	Rocco
    Mediate	 	 Non-affiliate	 	 	 	50,000	 	 	$	1.00	 	 	9/30/2021
	Angela
    Stanford	 	 Non-affiliate	 	 	 	50,000	 	 	$	1.00	 	 	9/30/2021
	Richard
    Sherman	 	 Non-affiliate	 	 	 	150,000	 	 	$	0.40	 	 	6/24/2022
	Private
    Rainmakers, Inc.	 	 Non-affiliate	 	 	 	500,000	 	 	$	0.50	 	 	7/20/2025
	Sean
    Folkson	 	 Affiliate	 	 	 	400,000	 	 	$	0.30	 	 	2/4/2022
	Spencer
    Clarke	 	 Non-affiliate	 	 	 	360,000	 	 	$	0.01	 	 	2/2/2026

 

    4

     

    

 

1.6 Summary
of Business.  The Company is a snack company focused on manufacturing and distribution of snacks is formulated to be more appropriate
for nighttime consumption. Nightfood ice cream was formulated by sleep and nutrition experts to satisfy nighttime cravings in a better,
healthier, more sleep-friendly way. Nightfood ice cream was originally manufactured in eight flavors. These are Full Moon Vanilla, Midnight
Chocolate, Cold Brew Decaf, After Dinner Mint Chip, Milk & Cookie Dough, Cherry Eclipse, Bed and Breakfast, and Cookies n’
Dreams. Additional flavors have been developed, both dairy, and non-dairy, for future introduction in 2020 based on retailer and consumer
demand. In February of 2020, Nightfood secured the endorsement of the American Pregnancy Association. With ice cream being the most widely
reported pregnancy craving, and with pickles being another food notorious for pregnancy cravings, the Company manufactured and launched
a ninth flavor, Pickles For Two. In February 2021, the Company announced its coming availability in Walmart stores and an in-store test
in hotel lobbies of a global hotel brand.

 

1.7 Information.
The Subscriber acknowledges receipt and full and careful review and understanding of this Subscription Agreement and the Prospectus
(the “Offering Documents”) and hereby represents that: (i) it has been furnished by the Company during the course
of this transaction with all information regarding the Company which it has requested; and (ii) that it has been afforded the opportunity
to ask questions of and receive answers from duly authorized officers of the Company concerning the terms and conditions of the Offering,
and any additional information which it has requested.

 

1.8 No
Representations or Warranties. The Subscriber hereby represents that, except as expressly set forth in the Offering Document, no
representations or warranties have been made to the Subscriber by the Company or any agent, employee or affiliate of the Company and
in entering into this transaction the Subscriber is not relying on any information other than that contained in the Offering Documents
and the results of independent investigation by the Subscriber.

 

1.9 Tax
Consequences. The Subscriber acknowledges that this Offering of the Shares may involve tax consequences and that the contents of
the Offering Documents do not contain tax advice or information. The Subscriber acknowledges that it must retain its own professional
advisors to evaluate the tax and other consequences of an investment in the Shares.

 

    5

     

    

 

1.10 Transfer
or Resale. The Subscriber understands that: (i) the Securities have not been and are not being registered under the 1933 Act or any
state securities laws, and may not be offered for sale, sold, assigned or transferred (each a “Disposition”)
unless (A) subsequently registered thereunder, (B) such Subscriber shall have delivered to the Company (if requested by the Company)
an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred
may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) such Subscriber provides the Company with
reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the
1933 Act (or a successor rule thereto) (collectively, “Rule 144”) or other applicable exemption; (ii) any sale of the Securities
made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any
resale of the Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules
and regulations of the SEC promulgated thereunder; and (iii) neither the Company nor any other person is under any obligation to register
the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder.

 

1.11 Legends.
The Subscriber understands that the certificates or other instruments representing the B Preferred shall bear a restrictive legend
in substantially the following form (and a stop-transfer order may be placed against transfer of such certificates or other instruments):

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITRIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR (B) AN OPINION OF
COUNSEL, IN A REASONABLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.

 

The
legend set forth above shall be removed and the Company shall issue a certificate or other instrument without such legend to the holder
of the Shares upon which it is stamped, if (a) there is in effect a registration statement under the 1933 Act covering the Disposition
and the Disposition is made in accordance with such registration statement or (b) if the Disposition of the Shares is completed in satisfaction
of the requirements of Rule 144 of the 1933 Act or other applicable exemption.

 

1.12 Validity;
Enforcement. If the Subscriber is a corporation, partnership, trust or other entity, the Subscriber represents and warrants that:
(a) it is authorized and otherwise duly qualified to purchase and hold the Shares; and (b) that this Subscription Agreement has been
duly and validly authorized, executed and delivered and constitutes the legal, binding and enforceable obligation of the undersigned.

 

1.13 Residency.
The Subscriber represents that its principal address is furnished at the end of this Subscription Agreement.

 

    6

     

    

 

1.14
NOTICE TO PROSPECTIVE PURCHASERS IN FLORIDA

 

These
Shares have not been registered under the Florida Shares Act in reliance upon an exemption therefrom. Any sale made pursuant to such
exemption is voidable by a Florida Purchaser within three (3) days after the first tender of consideration is made by such purchaser
to the issuer, an agent of the issuer or an escrow agent in payment for such Shares. However, this right is not available to any purchaser
who is a bank, trust company, savings institution, insurance company, Shares dealer, investment company as defined in the investment
company act of 1940, pension or profit-sharing trust or qualified institutional buyer as defined in Rule 144A under the Shares Act of
1933.

 

1.15 Foreign
Subscriber. If the Subscriber is not a United States person, such Subscriber hereby represents that it has satisfied itself as to
the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this
Subscription Agreement, including: (a) the legal requirements within its jurisdiction for the purchase of the Shares; (b) any foreign
exchange restrictions applicable to such purchase; (c) any governmental or other consents that may need to be obtained; and (d) the income
tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Shares. Such
Subscriber’s subscription and payment for, and his or her continued beneficial ownership of the Shares, will not violate any applicable
Shares or other laws of the Subscriber’s jurisdiction.

 

1.16 FINRA
Member. The Subscriber acknowledges that if it is a Registered Representative of an FINRA member firm, the Subscriber must give such
firm notice required by the FINRA’s Rules of Fair Practice, receipt of which must be acknowledged by such firm on the signature
page hereof.

 

 1.17 Confidential Information. The subscriber acknowledges that the information contained in this Subscription Agreement and the related schedules and Exhibits, as well as any other information relating to the Company that has been provided to the Subscriber in connection with this Offering is the confidential and proprietary information of the Company. The Subscriber agrees that he shall not disclose any of said information to any other person, except for his financial and legal advisors, who require such information to advise the Subscriber with respect to his contemplated investment, and in the event that the Subscriber does not invest in this Offering, he shall return all materials provided to him by the Company, including any copies thereof, to the Company.

 

 1.18 Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.

 

 1.19 Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

 

    7

     

    

 

II. REPRESENTATIONS
BY THE COMPANY

 

The
Company represents and warrants to the Subscriber, except as set forth in any disclosure schedules attached hereto:

 

2.1 Organization
and Qualification. The Company is duly organized and validly existing in good standing under the laws of Nevada and has the requisite
power and authorization to own its properties and to carry on its business as now being conducted. The Company is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of
the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good
standing would not have a Material Adverse Effect. As used in this Subscription Agreement, “Material Adverse Effect”
means any material adverse effect on the business, properties, assets, operations, results of operations or financial condition of the
Company, if any, taken as a whole, or on the transactions contemplated hereby, or by the other Offering Documents or the agreements and
instruments to be entered into in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations
under the Offering Documents.

 

2.2 Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations under
this Subscription Agreement and to perform its obligations hereunder, and to issue the Shares in accordance with the terms hereof. The
execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby,
including without limitation the issuance of the Shares, have been duly authorized by the Company’s board of directors and no further
consent or authorization is required by the Company, its board of directors or its stockholders. This Agreement has been duly executed
and delivered by the Company, and constitute valid and binding obligations of the Company enforceable against the Company in accordance
with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

    8

     

    

 

2.3 Capitalization.
The authorized, issued and outstanding Shares of the Company (including, but not limited to, all and/or other Shares convertible into
equity Shares of the Company and all options and warrants), are disclosed in Section 1.5(h) of this Subscription Agreement. All
of the issued and outstanding Shares of the Company have been and are, or upon issuance will be duly authorized, validly issued, fully
paid and non-assessable. All of the issued and outstanding Shares of the Company have been and are, or upon issuance will be duly authorized,
validly issued, fully paid and non-assessable. Except as disclosed in Offering Document, (i) no shares of the Company's capital stock
are subject to preemptive rights under Nevada law or any other similar rights or any liens or encumbrances suffered or permitted by the
Company; (ii) there are no outstanding debt securities Shares issued by the Company; (iii) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or Shares or rights convertible into or
exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the
Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or Shares or rights convertible into or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries;
(iv) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of
any of their Shares under the 1933 Act; (v) there are no outstanding Shares of the Company or any of its Subsidiaries which contain any
redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any
of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (vi) there are no Shares or
instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Shares as described in the Offering
Documents; and (vii) the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any
similar plan or agreement. All prior sales of Shares of the Company were either registered under the 1933 Act and applicable state Shares
laws or exempt from such registration, and no security holder has any rescission rights with respect thereto.

 

2.4 Issuance
of Shares; Reservation. The issuance, sale and delivery of the B Preferred has been duly authorized by all requisite corporate action
by the Company and, upon issuance in accordance with the Offering Documents, shall be (a) duly authorized, validly issued, fully paid
and non-assessable, (b) free from all taxes, liens and charges with respect to the issue thereof except that may be created by the Subscriber,
and (c) entitled to the rights and preferences set forth in the Shares. Assuming (i) the accuracy of the information provided by the
respective Subscribers in the Subscription Agreement and Questionnaire, and (ii) that all of the offerees and Subscribers are “accredited
investors” as such term is defined in Rule 501 of Regulation D or otherwise qualified by net assets and sophistication to invest,
the offer and sale of the Shares pursuant to the terms of this Subscription Agreement are and will be exempt from the registration requirements
of the 1933 Act and the rules and regulations promulgated thereunder. The Company is not disqualified from the exemption under Regulation
D by virtue of the disqualification contained in Rule 507 thereof or otherwise.

 

2.5 No
Conflicts. Except as set forth in the Offering Documents, the execution, delivery and performance of the Offering Documents by the
Company, the consummation by the Company of the transactions contemplated by the Offering Documents, and the issuance of the Shares and
performance by the Company of its obligations under the Offering Documents, will not (a) result in a violation of the Company’s
Certificate of Incorporation, any other certificate of designations, preferences and rights of any outstanding series of preferred stock
of the Company, or the Company’s By-Laws, (b) conflict with, or constitute a default or an event which with notice or lapse of
time or both would become a default under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
material agreement, note and/or other indebtedness, lease, license or instrument, or (c) result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state Shares laws and regulations and the rules and regulations of the NASD) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.

 

    9

     

    

 

2.6  Consents.
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court
or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Offering Documents. Except as otherwise provided in the Offering Documents, all consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the date hereof. The Company and its Subsidiaries are unaware of any facts or circumstances which might prevent the Company
from obtaining or affecting any of the foregoing.

 

2.7  No
General Solicitation. None of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf, has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act) in connection
with the offer or sale of the Shares.

 

2.8 No
Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, and any person acting on their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require
registration of any of the Shares under the 1933 Act by causing this Offering of the Shares to be integrated with prior offerings by
the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including without limitation, under the rules
and regulations of any exchange or automated quotation system on which any of the Shares of the Company are listed or designated, or
otherwise. None of the Company, its Subsidiaries, their affiliates and any person acting on their behalf will take any action or steps
referred to in the preceding sentence that would require registration of any of the Shares under the 1933 Act by causing the Offering
of the Shares to be integrated with other offerings, or otherwise.

 

2.9 Foreign
Corrupt Practices. Neither the Company, nor any director, officer, agent, employee or other person acting on behalf of the Company
or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company, (a) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; made any direct or indirect unlawful
payment to any foreign or domestic government official or employee from corporate funds, (b) violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or (c) made any unlawful bribe, rebate, payoff, influence payment, kickback
or other unlawful payment to any foreign or domestic government official or employee.

 

2.10 
Absence of Litigation. Except as set forth in the Offering Document, there is no action, suit, proceeding, inquiry or investigation
before or by the NASD, any court, public board, government agency, self-regulatory organization or body, or arbitrator pending or, to
the knowledge of the Company, threatened against the Company, the Common Stock or any of the Company’s officers or directors in
their capacities as such.

 

    10

     

    

 

2.11 Tax
Status. Except as set forth in this Offering Document, the Company and has made or filed all federal and state income and all other
tax returns, reports and declarations required by any jurisdiction to which it is subject, except when the failure to do so would not
have a Material Adverse Effect, and has paid all taxes and other governmental assessments and charges that are material in amount, shown
or determined to be due on such returns, reports and declarations or to the Company’s knowledge otherwise due and payable, except
those being contested in good faith and has set aside on its books reserves in accordance with GAAP reasonably adequate for the payment
of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in
any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for
any such claim.

 

2.12 Securities
Law Compliance. The offer, offer for sale, and sale of the B Preferred has not been registered with the SEC. The B Preferred are
to be offered, offered for sale and sold in reliance upon the exemptions from the registration requirements of Section 5 of the 1933
Act. The Company will conduct the Offering in compliance with the requirements of Regulation D under the 1933 Act, and the Company will
file all appropriate notices of offering with the SEC.

 

2.13 Title.
Except as set forth in or contemplated by the Offering Document, the Company has good and marketable title to all material properties
and tangible assets owned by it, free and clear of all liens, charges, encumbrances or restrictions, except as such as are not significant
or important in relation to the Company’s business; all of the material leases and subleases under which the Company is the lessor
or sublessor of properties or assets or under which the Company holds properties or assets as lessee or sublessee are in full force and
effect, and the Company is not in default in any material respect with respect to any of the terms or provisions of any of such leases
or subleases, and to the Company’s knowledge no material claim has been asserted by anyone adverse to rights of the Company as
lessor, sublessor, lessee or sublessee under any of the leases or subleases mentioned above, or affecting or questioning the right of
the Company to continued possession of the leased or subleased premises or assets under any such lease or sublease. The Company owns,
leases or licenses all such properties as are necessary to its operations as described in the Offering Documents.

 

2.14 Intellectual
Property Rights. The Company owns or possess adequate rights or licenses to use all trademarks, trade names, service marks, service
mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations,
trade secrets and rights necessary to conduct their respective businesses as now conducted, the lack of which could reasonably be expected
to have a Material Adverse Effect. Except as set forth in the Offering Documents, to the Company’s knowledge, none of the Company's
trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated, or are expected
to expire or terminate within two (2) years from the date of this Subscription Agreement, except where such expiration or termination
would not have either individually or in the aggregate a Material Adverse Effect. The Company does not have any knowledge of any infringement
by the Company of trademarks, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks,
service mark registrations, trade secrets or other similar rights of others, or of any such development of similar or identical trade
secrets or technical information by others and, except as set forth in the Offering Document, no claim, action or proceeding has been
made or brought against, or to the Company's knowledge, has been threatened against, the Company regarding trademarks, trade name rights,
patents, patent rights, inventions, copyrights, licenses, service names, service marks, service mark registrations, trade secrets or
other infringement, except where such infringement, claim, action or proceeding would not reasonably be expected to have either individually
or in the aggregate a Material Adverse Effect. Except as set forth in the Offering Document, the Company is unaware of any facts or circumstances
which might give rise to any of the foregoing. The Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their intellectual properties except where the failure to do so would not have either individually or in the aggregate
a Material Adverse Effect.

 

    11

     

    

 

2.15 Registration
Rights. Within 30 days after the Initial Closing of this Offering, the Company will file a resale registration statement on Form
S-1 (the “Registration Statement”) with respect to the Subscriber’s resale (including at prevailing market prices)
of all Shares underlying all B Preferred and Warrants and will use its commercially reasonable efforts to cause such Registration Statement
to be declared effective and answer any questions or comments from the Securities and Exchange Commission within 90 business days after
the Initial Closing of this Offering. Other than the holders of the B Preferred, no other person has any right to cause the Company to
affect the registration under the 1933 Act of any securities of the Company.

 

2.16 Brokers.
Neither the Company nor any of its officers, directors, employees or stockholders has employed any broker or finder in connection with
the transactions contemplated herein other than Spencer Clarke who shall receive compensation of an 8% commission on the proceeds of
the offering and certain warrants to purchase Shares.

 

2.17
Disclosure. None of the representations and warranties of the Company appearing in this Subscription Agreement or any information
appearing in any Exhibit or Schedule hereto other than material which says it is a “belief” or “expectation”
of the Company or similarly qualified, which statements the Company believes to the best of its knowledge as of the date hereof and at
each Closing Date to be true and accurate in all material respects and not misleading), when considered together as a whole, contains,
or on any Closing Date will contain, any untrue statement of a material fact or omits, or on any Closing Date will omit, to state any
material fact required to be stated herein or therein in order for the statements herein or therein, in light of the circumstances under
which they were made, not to be misleading.

 

2.18 Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the
receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers
any material, non-public information to a Purchaser without such Purchaser’s consent, the Company hereby covenants and agrees
that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective
officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided
that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction
Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

2.19 Furnishing
of Information. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the
Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to
the reporting requirements of the Exchange

 

2.20
Compensation for Buy-In on Failure to Timely Deliver Shares Upon Exercise and Conversion.  In addition to any other
rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares or
Common Stock (“Shares”) underlying Preferred Stock conversion in accordance with the terms of this agreement pursuant to
an exercise or conversion on or before the Share Delivery Date, and if after such date the Holder is required by its broker to
purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Shares which the Holder anticipated receiving upon such exercise or
conversion (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased
exceeds (y) the amount obtained by multiplying (1) the number of Shares that the Company was required to deliver to the Holder in
connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was
executed, and (B) at the option of the Holder, either reinstate the portion of the Shares and equivalent number of Warrant Shares or
Preferred Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the
Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and
delivery obligations hereunder.  For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to
cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss.  Nothing herein shall limit a Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.

 

    12

     

    

 

III. TERMS
OF SUBSCRIPTION

 

3.1
 Closing and Termination of Offering. Provided that the required conditions to closing set forth in Article V and
Article VI hereof have been satisfied or waived, a closing (the “Initial Closing”) shall take place
at the offices of the Company as set forth herein or at such place as may otherwise be agreed to by the Company within 30 days of the
receipt of the first cleared subscriber’s funds. The Company may consummate subsequent closings of the Offering, upon mutual agreement
only, each of which shall be subject to satisfaction or waiver of the conditions to closing set forth in Article V and
Article VI hereof, and each of which shall be deemed a “Closing” hereunder. The date of the last
closing of the Offering is hereinafter referred to as the “Final Closing” and the date of any Closing hereunder
is hereinafter referred to as a “Closing Date.” The offering period for the Offering shall commence on the
day the Offering Document is first delivered to prospective Subscribers by the Company for delivery in connection with the offering for
sale of the B Preferred and shall continue until the earlier to occur of: (i) the sale of the all of the B Preferred being offered pursuant
to this Offering; and (ii) 5:00 p.m. (New York Time), April 30, 2021; provided, however, that (A) if all of the B Preferred
have not been sold on or prior to April 30, 2021, this Offering may be extended for an additional ninety (90) days by the Company and
for additional 90 day periods thereafter in its sole discretion and (B) this Offering may be terminated prior to April 26, 2021, upon
the sole action of the Company. The day that the Offering Period terminates is hereinafter referred to as the “Termination
Date.”

 

3.2 Certificates.
The Subscriber hereby authorizes and directs the Company, upon each closing of the Offering, to deliver the certificates representing
the Shares (the “Stock Certificates”) to be issued to such Subscriber pursuant to this Subscription Agreement
to the Subscriber as restricted “book entry” shares at the Company’s transfer agent within three (3) days after the
applicable Closing Date.

 

IV. COVENANTS

 

4.1
Form D and Blue Sky. The Company shall file a Form D with respect to the B Preferred as required under Regulation D under the
1933 Act and, upon written request, provide a copy thereof to the Subscriber promptly after such filing. The Company shall use its reasonable
best efforts, on or before the Closing, to take such action as the Company shall reasonably determine is necessary in order to obtain
an exemption for or to qualify the B Preferred for sale to the Subscriber pursuant to this Subscription Agreement under applicable Securities
or “Blue Sky” laws of the states of the United States. The Company shall use its reasonable best efforts to make all filings
and reports relating to the offer and sale of the B Preferred required under applicable Securities or “Blue Sky” laws of
the states of the United States following the Closing.

 

    13

     

    

 

4.2
Use of Proceeds. The Company shall only use the net proceeds from the sale of the B Preferred: (i) Up to $1,300,000 in cash for
the repayment of variable rate convertible notes and (ii) the balance for its working capital requirements.

 

V. CONDITIONS
TO CLOSING IN FAVOR OF THE COMPANY

 

The
obligation of the Company hereunder to issue and sell B Preferred to the Subscriber at the Closing is subject to the satisfaction, at
or before the Closing, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and
may be waived by the Company at any time in its sole discretion by providing the Subscriber with prior written notice thereof:

 

5.1 Offering
Documents. The Subscriber shall have executed a Questionnaire, a Subscription Agreement and delivered the same to the Company.

 

5.2 Purchase
Price. The Subscriber shall have paid the purchase price for the B Preferred being purchased by the Subscriber at the Closing in
the manner set forth in Section 1.1.

 

5.3 Representations
and Warranties. The representations and warranties of the Subscriber shall be true and correct in all material respects as of the
date when made and as of the Closing as though made at that time, and the Subscriber shall have performed, satisfied and complied in
all material respects with the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied
or complied with by the Subscriber at or prior to the Closing.

 

5.4 Other
Matters. All opinions, certificates and documents and all proceedings related to this Offering shall be in form and content reasonably
satisfactory to the Company and its legal counsel.

 

VI. CONDITIONS
TO CLOSING IN FAVOR OF THE SUBSCRIBER

 

The
obligation of the Subscriber hereunder to purchase the Shares is subject to the satisfaction, at or before the Closing, of each of the
following conditions, provided that these conditions are for the Subscriber’s sole benefit and may be waived by the Subscriber
at any time in its sole discretion by providing the Company with prior written notice thereof:

 

6.1 Offering
Documents. The Company shall have executed and delivered to the Subscriber each of the Offering Documents to which its signature
is required.

 

6.2 Representations
and Warranties. The representations and warranties of the Company shall be true and correct as of the date when made and as of the
Closing as though made at that time (except for representations and warranties that reference a specific date which shall have been true
and correct in all material respects as of such date), and the Company shall have performed, satisfied and complied in all respects with
the covenants, agreements and conditions required by the Offering Documents to be performed, satisfied or complied with by the Company
at or prior to the Closing.

 

6.3
Filing of Certificate of Designation. A Certificate of Designation, substantially equivalent to the draft certificate of designation
appended hereto, shall have been filed with the Secretary of State of the State of Nevada.

 

VII. RIGHTS
OF TERMINATION

 

7.1 Termination
by Subscriber or Company. This Subscription Agreement may be terminated at any time prior to the Closing: (a) by mutual written consent
of the parties hereto; or (b) by the Company or the Subscriber upon written notice to the other party if any court or governmental authority
of competent jurisdiction shall have issued a final, non-appealable order restraining, enjoining or otherwise prohibiting the consummation
of the transactions contemplated by this Subscription Agreement. Termination of this Subscription Agreement under this Section
7.1 shall result in this Subscription Agreement becoming void and of no further force and effect, except that a termination shall
not release, or be construed as so releasing, any party hereto from any liability or damage to the other party hereto arising out of
the breaching party’s willful and material breach of the warranties and representations made by it, or willful and material failure
in performance of any of its covenants, agreements, duties or obligations provided hereunder, and the obligations under Section
8.8 shall survive such termination.

 

VIII. MISCELLANEOUS

 

8.1 Notice.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Subscription Agreement
must be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally, (b) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party),
or (c) one (1) business day after deposit with an overnight courier service, in each case properly addressed to the party to receive
the same. The addresses and facsimile numbers for such communications shall be:

 

If
to the Company at the address set forth in the first paragraph of this agreement, Attn.: President.

 

    14

     

    

 

If
to the Subscriber, to its address and facsimile number set forth at the end of this Subscription Agreement, or to such other address
and/or facsimile number and/or to the attention of such other person as specified by written notice given to the Company five (5) days
prior to the effectiveness of such change.

 

Written
confirmation of receipt (a) given by the recipient of such notice, consent, waiver or other communication, (b) mechanically or electronically
generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page
of such transmission, or (c) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from an overnight courier service in accordance with clauses (a), (b) or (c) above, respectively.

 

8.2 Entire
Agreement; Amendment. This Subscription Agreement supersedes all other prior oral or written agreements between the Subscriber, the
Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Subscription Agreement
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and
therein and, except as specifically set forth herein or therein, neither the Company nor the Subscriber makes any representation, warranty,
covenant or undertaking with respect to such matters. No provision of this Subscription Agreement may be amended or waived other than
by an instrument in writing signed by the Company and each Subscriber.

 

8.3 Severability.
If any provision of this Subscription Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
shall not affect the validity or enforceability of the remainder of this Subscription Agreement in that jurisdiction or the validity
or enforceability of any provision of this Subscription Agreement in any other jurisdiction.

 

8.4 Governing
Law; Jurisdiction. This Agreement shall be governed by and construed solely in accordance with the internal laws of the State of
New York with respect to contracts executed, delivered and to be fully performed therein, without regard to the conflicts of laws principles
thereof. The parties hereto hereby expressly and irrevocably agree that any suit or proceeding arising under this Agreement or the consummation
of the transactions contemplated hereby, shall be brought solely in a federal or state court located in the County of Westchester, State
of New York. By its execution hereof, Company and Subscriber hereby expressly and irrevocably submits to the in personam
jurisdiction of the federal and state courts located in the County of Westchester, State of New York and agree that any process in any
such action may be served upon him, her, or it personally, or by certified mail or registered mail upon such party or such agent, return
receipt requested, with the same full force and effect as if personally served upon such party in Tarrytown, New York. The parties hereto
each waive any claim that any such jurisdiction is not a convenient forum for any such suit or proceeding and any defense or lack of
in personam jurisdiction with respect thereto. In the event of any such action or proceeding, the party prevailing therein
shall be entitled to payment from the other party hereto of its reasonable counsel fees and disbursements.

 

8.5 Headings.
The headings of this Subscription Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Subscription Agreement.

 

    15

     

    

 

8.6 Successors
and Assigns. This Subscription Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns, including any purchasers of the Shares. The Company shall not assign this Subscription Agreement or any rights or obligations
hereunder. Subscriber may assign some or all of its rights hereunder without the consent of the Company, provided, however,
that any such assignment shall not release the Subscriber from its obligations hereunder unless such obligations are assumed by such
assignee and the Company has consented to such assignment and assumption, which consent shall not be unreasonably withheld.

 

8.7 No
Third-Party Beneficiaries. This Subscription Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

8.8 Survival.
The representations and warranties of the Company and the Subscriber contained in Article I and Article II
and the agreements set forth this Article VIII shall survive the Closing for a period of twelve (12) months.

 

8.9 Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Subscription Agreement and the consummation of the transactions contemplated
hereby.

 

8.10 No
Strict Construction. The language used in this Subscription Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

8.11 Legal
Representation. The Subscriber acknowledges that: (a) it has read this Subscription Agreement and the exhibits hereto; (b) it understands
that the Company has been represented in the preparation, negotiation, and execution of this Subscription Agreement by Frank Hariton,
Esq., counsel to the Company; (c) it has either been represented in the preparation, negotiation, and execution of this Subscription
Agreement by legal counsel of its own choice, or has chosen to forego such representation by legal counsel after being advised to seek
such legal representation; and (d) it understands the terms and consequences of this Subscription Agreement and is fully aware of its
legal and binding effect.

 

8.12 Confidentiality.
The Subscriber agrees that it shall keep confidential and not divulge, furnish or make accessible to anyone, the confidential information
concerning or relating to the business or financial affairs of the Company contained in the Offering Documents to which it has become
privy by reason of this Subscription Agreement.

 

8.13 Counterparts.
This Subscription Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that
a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect
as if the signature were an original, not a facsimile signature.

 

Remainder
of Page Intentionally Left Blank

 

    16

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Subscription Agreement as of the date first written above.

 

	SUBSCRIBER
    **	 	CO-SUBSCRIBER
    **
	 	 	 
	 	 	 
	Signature
    of Subscriber	 	Signature
    of Co-Subscriber
	 	 	 
	 	 	 
	Name
    of Subscriber [please print]	 	Name
    of Co-Subscriber [please print]
	 	 	 
	 	 	 
	Address
    of Subscriber	 	Address
    of Co-Subscriber
	 	 	 
	 	 	 
	Social
    Security or Taxpayer

    Identification
    Number of Subscriber
	 	Social
    Security or Taxpayer Identification

    Number
    of Co-Subscriber

	 

    Name
    of Holder(s) as it should appear on the security certificates* [please print]
	 
	 	 	 	 

		*	Please
provide the exact names that you wish to see on the certificates

 

		(1)	For
individuals, print full name of subscriber.

		(2)	For
joint, print full name of subscriber and all co-subscribers.

		(3)	For
corporations, partnerships, LLC, print full name of entity, including “&,” “Co.,” “Inc.,” “etc,”
“LLC,” “LP,”etc.

		(4)	For
Trusts, print trust name (please contact your trustee for the exact name that should appear on the certificates.)

 

Dollar
Amount of B Preferred Subscribed For at $1,000 per Unit: $                                           

 

	 	Dollar
Amount of B Preferred

Subscription
Accepted: $                           

	 	 
	 	SUBSCRIPTION ACCEPTED BY THE COMPANY
	 	 	 
	 	NightFood Holdings, Inc.
	 	 	 
	 	By:	 
	 	 	Sean
Folkson, President & CEO

 

**If
Subscriber is a Registered Representative with a FINRA (formerly NASD) member firm or an affiliated person of a FINRA member firm, have
the acknowledgment to the right signed by the appropriate party:

 

The
undersigned FINRA Member firm acknowledges receipt of the notice required by Rule 3040 of the FINRA Conduct Rules.

 

Name
of FINRA Member Firm

 

	By:	 	 
	 	Authorized
Officer	 

 

 

17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]